The pitch for a new biologic is often about potency. For Nanogrow, the pitch is about precision. The Pamplona-based biotech startup is developing therapies based on camelid-derived nanobodies, but its wedge isn't just the molecule. It's the delivery method: a cream, an inhaler, a localized injection. The bet is that by avoiding the systemic bloodstream route, these smaller, more stable antibodies can treat conditions like psoriasis or asthma with fewer side effects and better patient compliance [Perplexity Sonar Pro Brief, retrieved 2024]. It's a pragmatic approach for a young company, one that chooses to fight on the battlefield of administration rather than pure discovery against pharmaceutical giants.
Founded in 2021 by CEO Nicolás Galmarini and Chief Scientific Officer Lucía Vanrell, Nanogrow operates with a dual focus on human and veterinary pharmaceutical applications [Navarra Health Cluster, January 2025]. The company's early traction is measured in awards and seed capital, not yet in clinical trials. It secured a $1.2 million seed round in March 2024 [Perplexity Sonar Pro Brief, retrieved 2024] and has since been recognized as the "most disruptive" startup at South Summit Brazil in April 2025 [Uruguay XXI, April 2025]. More recently, it won a local Startup World Cup edition in September 2026, earning a shot at a $1 million prize in San Francisco [El Observador, September 2026]. For a preclinical-stage company, this kind of visibility is a currency, used to attract advisors, talent, and the next round of funding.
The Platform Bet: Local Over Systemic
Nanogrow's technical foundation rests on single-domain antibodies, often called nanobodies or VHHs. These are smaller and simpler than conventional monoclonal antibodies, which makes them potentially more stable and easier to produce. The company's stated innovation is applying this platform to localized delivery. Their research targets include psoriasis, melanoma, atopic dermatitis, and asthma,conditions where a topical cream or inhaled mist could theoretically deliver the drug directly to the affected tissue [Perplexity Sonar Pro Brief, retrieved 2024].
This focus dictates a specific development path. Instead of pursuing blockbuster intravenous drugs for widespread cancers, Nanogrow is looking at niches where localized application is not just a novelty but a clinical advantage. For a veterinary application, an easier-to-administer treatment could mean a significant compliance boost. The strategy is capital-efficient, aiming to prove the platform in smaller, defined markets before scaling. Since relocating to the CEIN accelerator in Navarra, the team has added three expert advisors and six professionals, building out the operational side of the bet [CEIN, March 2026].
Founder Credentials and Early Traction
The founding team brings a blend of commercial and deep scientific expertise. Nicolás Galmarini, the CEO, brings over 15 years of experience in the pharmaceutical industry, according to company profiles [Perplexity Sonar Pro Brief, retrieved 2024]. His co-founder, Lucía Vanrell, is a biochemist with a PhD from the University of Navarra and serves as the CSO, providing the foundational research credibility [Perplexity Sonar Pro Brief, retrieved 2024]. Vanrell was also recognized as "Emprendedora Navarra 2025," highlighting the local ecosystem's support [Uruguay XXI, November 2025].
Their early traction is less about revenue and more about validation through competition and ecosystem recognition. The table below summarizes their public milestones to date.
| Milestone | Date | Source |
|---|---|---|
| Seed Round ($1.2M) Closed | March 2024 | [Perplexity Sonar Pro Brief, retrieved 2024] |
| "Most Disruptive" Startup, South Summit Brazil | April 2025 | [Uruguay XXI, April 2025] |
| Lucía Vanrell named "Emprendedora Navarra 2025" | 2025 | [Uruguay XXI, November 2025] |
| Wins local Startup World Cup edition | September 2026 | [El Observador, September 2026] |
| Innovation Award, Cadena SER Navarra | Not Specified | [Navarra Health Cluster, January 2025] |
The Realistic Competitive Set
Nanogrow is not inventing the nanobody. That field was pioneered by companies like Ablynx, which was acquired by Sanofi for €3.9 billion in 2018 [Crunchbase]. The competitive landscape is dominated by large pharma with immense R&D budgets. Merck & Co, Novartis, and Boehringer Ingelheim all have active nanobody programs [Perplexity Sonar Pro Brief, retrieved 2024]. For a startup, competing on raw molecule discovery against these players is a daunting, capital-intensive proposition.
Nanogrow's answer is to narrow the battlefield. Its realistic competition isn't the broad nanobody platform of Sanofi, but the specific, localized formulation projects that may be lower on a giant's priority list. The company's initial ideal customer profile is likely a mid-sized pharmaceutical or animal health company looking to in-license a novel delivery mechanism for a known therapeutic area. The pitch would be about de-risking a localized approach and owning a specialized application, rather than funding foundational science from scratch.
The Capital and Clinical Road Ahead
The $1.2 million seed round is a start, but it's a modest war chest for biotech development. The next twelve months will be critical for Nanogrow to convert its award-winning platform into tangible assets that attract a Series A. The key milestones to watch are preclinical data packages for its lead programs, likely in dermatology or respiratory care. A partnership or licensing deal with an established pharma player would be a strong signal of technical validation and provide non-dilutive capital.
The company's presence in both Uruguay and Spain provides access to different grant and accelerator networks, like CEIN, which can extend the runway [Uruguay XXI, November 2025]. However, the path from platform to product is long. The most credible risk is the sheer timeline and cost of biologic development, even for localized therapies. Nanogrow's most plausible counter is to stay focused on its wedge,proving that its delivery methods work in a specific, tractable model,and use that proof to fund the next step, rather than attempting to build a full pipeline alone.
Sources
- [Navarra Health Cluster, January 2025] Nanogrow Biotech, the startup specialising in the development of dermatological treatments based on nanoantibodies | https://navarrahealthcluster.com/en/nanogrow-biotech-the-startup-specialising-in-the-development-of-dermatological-treatments-based-on-nanoantibodies/
- [Uruguay XXI, April 2025] Uruguayan Startup Nanogrow Crowned Most Disruptive Company at South Summit Brazil | https://www.uruguayxxi.gub.uy/en/news/article/uruguayan-startup-nanogrow-crowned-most-disruptive-company-at-south-summit-brazil/
- [Uruguay XXI, November 2025] Nanogrow Biotech: Uruguayan science that crosses borders and strengthens its presence in Europe | https://www.uruguayxxi.gub.uy/en/news/article/nanogrow-biotech-uruguayan-science-that-crosses-borders-and-strengthens-its-presence-in-europe/
- [CEIN, March 2026] Nanogrow: Targeted biological treatments using nanoantibodies | https://www.cein.es/en/blog/2025/nanogrow-tratamientos-biologicos-localizados-con-nanoanticuerpos
- [El Observador, September 2026] La biotecnológica Nanogrow ganó la edición local de Startup World Cup | https://www.elobservador.com.uy/cafe-y-negocios/la-biotecnologica-nanogrow-gano-la-edicion-local-startup-world-cup-y-viajara-san-francisco-competir-us-1-millon-n6056471
- [Perplexity Sonar Pro Brief, retrieved 2024] Company overview and product claims
- [Crunchbase] Sanofi's acquisition of Ablynx | https://www.crunchbase.com/organization/nanogrow-biotech